Thymidylate synthase inhibitors

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 227-243

  Touroutoglou, Nikolaos ^a   Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ENZYME INHIBITOR; METESIND GLUCURONATE; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; GENES, P53; HUMANS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0029928146     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Ayusawa, D., Arai, H., Wataya, Y., and Sento, T. A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutat. Res., 200: 221-230, 1988.
2. Grem, J. L. Fluorinated pyrimidines. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 180-224. Philadelphia: J. B. Lippincott Company, 1990.
3. Harrap, K. R., Jackman, A. L., Newell, D. R , Taylor, G. A., Hughes, L. R., and Calvert, A. H. Thymidylate synthase: a target for anticancer drug design. Adv. Enzyme Regul., 29: 161-179, 1989.
4. Roth, B., and Cheng, C. C. Recent progress in the medicinal chemistry of 2,4-diaminopyridines. Prog. Med. Chem., 19: 269-331, 1982.
5. Sirotnak, F. M., Burchall, J. J., Ensminer, W. D., and Montgomery, J. A. Folate Antagonists as Therapeutic Agents, Vol. 1. Cambridge: Academic Press, 1984.
6. Fischer, G. A. Defective transport of amethopterin (methotrexate) as a mechanism of resistance to antimetabolites in L5178Y cells. Biochem. Pharmacol., 11: 1233-1234, 1962.
7. Harrap, K. R., Hill, B. T., Furness, M. E., and Hart, L. I. Sites of action of amethopterin in intrinsic and acquired drug resistance. Ann. NY Acad. Sci., 186: 312-324, 1971.
8. Kessel, D., Hall, T. C., and Roberts, D. Modes of uptake of methotrexate by normal and leukemic human leukocytes in vitro and their relation to drug response. Cancer Res. 28: 564-570, 1968.
9. Bertino, J. R., and Romanini, A. Chemotherapeutic agents: folate antagonists. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Dufe, D. Morton, and R. Weichselbaum (eds.), Cancer Medicine, Vol. 1, pp. 698-711. Philadelphia: Lea & Febiger, 1993.
10. Heidelberger, C. Fluorinated pyrimidines. Prog. Nucleic Acid Res., 4: 1-50, 1965.
11. Heidelberger, C. Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges - G. H. A. Clowes Memorial Lecture. Cancer Res., 30: 1549-1569, 1970.
12. Schuetz, J. D., Wallace, H. J., and Diasui, R. B. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res., 44: 1358-1363, 1984.
13. Peters, J. G., van Groeningen, C. J., Van der Wilt, C., Meijer, S., Smid, K., Laurensse, E., and Pinedo, H. M. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin. Oncol , 19 (2 Suppl. 3): 26-35, 1992.
14. Keyomarsi, K., and Moran, R. G. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res., 46: 5229-5235, 1986.
15. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K., Allegra, C. J., Danenberg, P., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
16. Johnston, P. G , Drake, J. C., Trepel, J., and Allegra, C. J. The immunological quantitation of thymidylate synthase using the monoclonal antibody TS106 in 5-FU-sensitive and -resistant human cancer cell lines. Cancer Res., 52: 4302-4312, 1992.
17. Peters, G. J., van der Wilt, C. L., van Groeningen, C. J., Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol., 12: 2035-2042, 1994.
18. Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., and Allegra, C. J. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890-899, 1989.
19. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
20. Jansen, G., Westerhof, G. R., Jarmuszewski, M. J., Kathmann, I., Rijksen, G., and Schornagel, J. H. Methotrexate transport in variant human ccrf-cem leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J. Biol. Chem., 265: 18272-18277, 1990.
21. Balinska, M., Galivan, J., and Coward, J. K. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res., 41: 2751-2756, 1981.
22. Hoffbrand, A. V., Tripp, E., Houlihan, C. M., and Scott, J. M. Studies on the uptake of synthetic conjugated folates by human marrow cells. Blood., 42: 141-146, 1973.
23. Calabresi, P., and Chabner, B. A. Antineoplastic agents. In: A. Goodman Gilman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), Goodman and Gilman's The Pharmacologic Basis of Therapeutics, pp. 1223-1227. New York: Pergamon Press, 1990.
24. 10-substituted-5,8-dideazafolates. Adv. Enzyme Regul., 31: 13-27, 1991.
25. Hardy, L. W., Finer-Moore, J. S., Montfort, W. R., Jones, M. O., Santi, D. V., and Stroud, R. M. Atomic structure of thymidylate synthase: target for rational drug design. Science (Washington DC), 235: 448-455, 1987.
26. Matthews, D. A., Villafranca, J. E., Janson, C. A., Smith, W. W., Welsh, K., and Freer, S. Stereochemical mechanism of action for thymidylate synthase based on the X-ray structure of the covalent inhibitory ternary complex with 5-fluoro-2-deoxyuridylate and 5,10-methylenetetrahydrofolate. J. Mol. Biol., 214: 937-948, 1990.
27. Montfort, W. R., Perry, K. M., Fauman, E. C., Finer-Moore, J S., Maley, G. F., Hardy, L., Maley, F., and Stroud, R. M. Structure, multiple site binding, and segmentai accommodation in thymidylate synthase on binding dUMP and an anti-folate. Biochemistry, 29: 6964-6977, 1990.
28. Matthews, D. A., Appelt, K., Oatley, S. J., and Xuong, N. H. Crystal structure of Escherichia coli thymidylate synthase containing bound 5-fluoro-2′-deoxyuridylate and 10-propargyl-5,8-dideazafolate. J. Mol. Biol., 214: 923-936, 1990.
29. Appelt, K., Bacquet, F. J., Bartlett, C. A., Booth, C. L. J., and Freer, S. T. Design of enzyme inhibitors using iterative protein crystallographic analysis. J. Med. Chem., 34: 1925-1934, 1991.
30. Kamb, A., Finer-Moore, J., Calvert, H., and Stroud, R. Structural basis for recognition of polyglutamyl folates by thymidylate synthase. Biochemistry, 31: 9883-9890, 1992.
31. Kamb, A., Finer-Moore, J. S., and Stroud, R Cofactor triggers the conformational change in thymidylate synthase: implications for an ordered binding mechanism. Biochemistry, 31: 12876-12884, 1992.
32. Matthews, D. A., Appelt, K., and Oatley, S. J. Stacked β-bulges in thymidylate synthase account for a novel right-handed rotation between opposing β sheets. J. Mol Biol., 205: 449-454, 1989.
33. Danenberg, K. D., and Danenberg, P. V. Evidence for a sequential interaction of the subunits of thymidylate synthetase. J Biol Chem., 254: 4335-4348, 1979.
34. Stroud, R. M., and Finer-Moore, J. S. Stereochemistry of a multi-step/bipartite methyl transfer reaction: thymidylate synthase. FASEB J., 7: 671-677, 1993.
35. Dev, I. K., Dallas, W. S., Ferone, R., Hanlon, M., McKee, D. D., and Yates, B. B. Mode of binding of folate analogs to thymidylate synthase. Evidence of two asymmetric but interactive substrate binding sites. J. Biol. Chem., 269: 1873-1882, 1994.
36. Weichsel, A., Montfort, W., Ciesla, J., and Maley, F. Promotion of purine nucleotide binding to thymidylate synthase by a potent folate analogue inhibitor, 1843U89. Proc. Natl. Acad. Sci. USA, 92: 3493-3497, 1995.
37. Pogolotti, A. L. J., Danenberg, P. V., and Santi, D. V. Kinetics and mechanism of interaction of 10-propargyl-5,8-dideazafolate with thymidylate synthase. J. Med. Chem., 29: 478-482, 1986.
38. Santi, D. V., McHenry, C. S., Raines, R. T., and Ivanetich, K. M. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry, 26: 8606-8613, 1987.
39. 10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem. Pharmacol., 37: 4047-4054, 1988.
40. Lu, Y-Z., Aiello, P. D., and Matthews, R. G. Studies on the polyglutamate specificity of thymidylate synthase from fetal pig liver. Biochemistry, 23: 6870-6876, 1984.
41. Jones, T. R., Calvert, A. H., Jackman, A. L., Brown, S. J., Jones, M., and Harrap, K. R. A potent antitumour quinazoline inhibitor of thymidylate synthase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer, 17: 11-19, 1981.
42. Jackman, A. L., Jodrell, D. I., Gibson, W., and Stephens, T. C. ICI D1694, an inhibitor of thymidylate synthase for clinical study. In: R. A. Harkness, G. B. Elion, and N. Zollner (eds.), Purine and Pyrimidine Metabolism in Man, Vol. VII, Part A, pp. 19-23. New York: Plenum Press, 1991.
43. 10-propargyl-5,8-dideazafolic Acid (CB 3717). Natl. Cancer Inst. Monogr., 5: 213-218, 1987.
44. Jackson, R. C., Jackman, A. L., and Calvert, A. H. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells. Biochem. Pharmacol., 32: 3783-3790, 1983.
45. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol., 33: 3269-3275, 1984.
46. 10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat. Rep., 70: 971-979, 1986.
47. 10propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue, ICI D1694, in mice. Br. J. Cancer. 64: 833-838, 1991.
48. 10-propargyl-5,8-dideazafolic acid, CB 3717. J. Clin. Oncol., 4: 1245-1252, 1986.
49. 10-propargyl 5,8-dideazafolic acid. Eur. J. Cancer & Clin. Oncol., 24: 201-204, 1988.
50. 10-propargyl-5,8-dideazafolic acid, CB3717. Eur. J. Cancer & Clin Oncol., 24: 769-775, 1988.
51. 10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur. J Cancer & Clin. Oncol., 24. 733-736, 1988.
52. Bassendine, M. F., Curtin, N. J., Loose, H., Harris, A. L., and James, O. F. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor CB 3717: a Phase II study. J Hepatol., 4: 349-356, 1987.
53. Newell, D. R., Siddik, Z. H., Calvert, A. H., Jackman, A. L., Alison, D. L., McGhee, G. K., and Harrap, K. R. Pharmacokinetics and toxicity studies with CB3717 Proc. Am. Assoc. Cancer Res., 23: 181, 1982.
54. Marsham, P. R., Hughes, L. R., Jackman, A. L., Hayter, A. J., Oldfield, J., Wardleworth, J. M., Bishop, J. A. M., O'Connor, B. M., and Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J. Med. Chem., 34: 1594-1605, 1991.
55. Jackman, A. L., Taylor, G. A., Bishop, J. A., O'Connor, B. M., Bisset, G., Hughes, L. R , Moran, R. G., and Calvert, A. Biochemical aspects of a new thymidylate synthase inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31: 342, 1990.
56. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L 1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
57. Erlichman, C., and Mitrovski, B. Biochemical effects of D1694 inhibition of thymidylate synthase in MGH-U1 bladder cancer cells. Proc. Am. Assoc. Cancer Res., 33: 507, 1992.
58. Arredondo, M. A., Guimaraes, M. A., Yin, M. B., Slocum, H. K., and Rustum, Y. M. Prolonged cell cycle phase perturbation induced by the quinazoline antifolate thymidylate synthase inhibitor ICI D1694. Proc. Am. Assoc. Cancer Res., 33: 428, 1992.
59. Kelland, L. R., Abel, G., Brown, M., and Jackman, A. L. Cytotoxicity of ICI D 1694 and cisplatin in sensitive and acquired resistant tumor cell lines. Br J. Cancer, 65 (Suppl. 16): 64, 1992.
60. Zhang, Z. G., Yin, M. B., and Rustum, Y. M. Cytotoxicity, DNA strand breaks, thymidylate synthase inhibition and methylenetetrahydrofolate pool decrease induced by ICI D 1694. Proc. Am. Assoc. Cancer Res., 33: 410, 1992.
61. Matsui, S., Lu, K., Wrzosek, C., and Rustum, Y. Double-strand DNA damage induced by thymidylate synthase (TS) inhibitor, ZD1694, in human colon carcinoma cell, HCT-8, requires DNA replication. Proc. Am. Assoc. Cancer Res., 36: 378, 1995.
62. Stephens, T. C , Calvete, J. A., Janes, D., Waterman, S. E., Valcaccia, B. E., Hughes, L. R., and Calvert, A. H. Antitumor activity of a new thymidylate synthase (TS) inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31: 342, 1990.
63. Jodrell, D. I., Newell, D. R., Calvete, J A., Stephens, T. C., and Calvert, A. H. Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase (TS) inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31: 341, 1990.
64. Stephens, T. C., Valcaccia, B. E., Sheader, M. L., Hughes, L., and Jackman, A. L. The thymidylate synthase (TS) inhibitor ICI D 1694 is superior to CB3717, 5-fluorouracil (5-FU) and methotrexate (MTX) against a panel of human tumor xenografts. Proc. Am. Assoc. Cancer Res., 32: 328, 1991.
65. Jackman, A. L., Farrugia, D. C., Clarke, S. J., Aherne, G. W., Boyle, F. T., Seymour, L., Azab, M., and Kennealey, G. Delayed rescue of ZD1694 toxicity in BALB/c mice with thymidine (dThd) or leucovorin (LV). Proc. Am. Assoc. Cancer Res., 36: 377, 1995.
66. Aherne, G. W., Farrugia, D. C , Ward, E., Sutcliffe, F., and Jackman, A. L. ZD1694 (Tomudex) and polyglutamate levels in mouse plasma and tissues measured by radioimmunoassay (RIA) and the effect of leucovorin (LV). Proc. Am. Assoc. Cancer Res., 36: 376, 1995.
67. The International Medical Function. Tomudex (ZD1694), a Thymidylate Synthase Inhibitor: Clinical Investigator's Manual. Macclesfield, United Kingdom: Zeneca Pharmaceuticals, 1994
68. Jodrell, D. I., Newell, D. R , Gibson, W., Hughes, L. R., and Calvert, A. H. The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats. Cancer Chemother. Pharmacol., 28: 331-338, 1991.
69. Jackman, A. L., and Gibson, W. Polyglutamation of the thymidylate synthase (TS) inhibitor, ZD1694 (Tomudex), in normal mouse tissues. Proc. Am. Assoc. Cancer Res., 36. 377, 1995.
70. Judson, I., Clarke, S., Ward, J., Sutcliffe, F., Planting, A., Spiers, J., Smith, R., Verweij, J., and Judson, I. Pharmacokinetics of ICI D1694 following a 15-minute infusion in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 11: 117, 1992.
71. Clarke, S. J., Ward, J., Tierney, K., Walker, M., Sutcliffe, F., Planting, A., Verweij, J , Spiers, J., Smith, R., and Judson, I. Phase I and pharmacokinetic study of ICI D1694: a folate-based thymidylate synthase (TS) inhibitor. Ann. Oncol., 3 (Suppl. 1): 135, 1992.
72. Clarke, S. J., Ward, J., Planting, A., Spiers, J., Smith, R., Verweij, J., and Judson, I. Phase I trial of ICI D 1694: a novel thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 33: 406, 1992.
73. Clarke, S. J., Jackman, A. L., and Judson, I. R. The toxicity of ICI D1694 in man and mouse. Adv. Exp. Med. Biol., 338: 601-604, 1993.
74. Clarke, S. J., Ward, J., De Boer, M., Planting, A., Verweij, J., Sutcliffe, F., Azab, M., and Judson, I. Phase I study of the new thymidylate synthase inhibitor "Tomudex" (ZD1694) in patients with advanced malignancy. Ann. Oncol., 5 (Suppl. 5): 132, 1994.
75. Sorensen, J. M., Jordan, D., Grem, J. L., Hamilton, J. M., Arbuck, S. G., Johnson, P., Kohler, D. R., Goldspiel, B. R., and Allegra, C. J. Phase I trial of D1694, a pure thymidylate synthase inhibitor. Proc. Am. Soc. Clin. Oncol., 12: 158, 1993.
76. Sorensen, J. M., Jordan, E., Grem, J. L., Arbuck, S. G., Chen, A. P., Hamilton, J. M., Johnson, P., Kohler, D., Goldspiel, B., and Allegra, C. Phase I trial of ZD1694 ("Tomudex") a direct inhibitor of thymidylate synthase. Ann. Oncol., 5 (Suppl. 5): 132, 1994.
77. Gore, M., Earl, H., Cassidy, J., Tattersal, M., Mansi, J., and Azab, M. Phase II study of "Tomudex" (ZD1694), a new thymidylate synthase inhibitor with antitumour activity in breast cancer. Ann. Oncol., 5 (Suppl. 5): 132, 1994.
78. Smith, I. E , Spielmann, M., Bonneterre, J., Namer, M., Green, M., Wander, H. E., Toussaint, C., and Azab, M. "Tomudex" (ZD1694), a new thymidylate synthase inhibitor ZD1694 in advanced breast cancer. Ann. Oncol , 5 (Suppl. 5): 132, 1994.
79. Smith, I. E., Spielmann, M., Namer, M., Bonneterre, J., Wander, H. E., Green, M., Lowery, K., and Azab, M. Antitumour activity of a new thymidylate synthase inhibitor ZD1694 in advanced breast cancer. Breast Cancer Res. Treat., 27: 149, 1993.
80. Zalcberg, J., Cunningham, D., Banc Custsem, E., Francois, J. E., Schornagel, J. H., Adenis, A., Green, M., Starkhammer, H., and Azab, M. Good antitumour activity of the new thymidylate synthase inhibitor "Tomudex" (ZD1694) in colorectal cancer. Ann Oncol., 5 (Suppl. 5): 133, 1994.
81. Pazdur, R., Casper, E. S., Meropol, N. J., Fuchs, C., and Kennealey, G. T. Phase II trial of "Tomudex" (ZD1694), a thymidylate synthase inhibitor in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 13: 207, 1994.
82. Gore, M., Earl, H., Cassidy, J., Tattersal, M., Mansi, J., and Azab, M. Phase II study of Tomudex (ZD1694) in refractory ovarian cancer Ann. Oncol., 5 (Suppl 5): 133, 1994.
83. Burris, H. I., Von Hoff, D., Bowen, K., Heaven, R., Rinaldi, D., Eckardt, J., Campbell, L., Robert, F., Patton, S., and Kennealey, G. A Phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Ann. Oncol , 5 (Suppl. 5): 133, 1994.
84. Cunningham, D., Zalcberg, J., Francois, E., Van Cutsem, J. H., Ellis, P., and Azab, M. Tomudex (ZD1694). a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol., 13: 199, 1994.
85. Piedbois, P., Buyse, M., Rustum, Y , Machover, D., Erlichman, C., Carlson, R. W., Valone, F., Labianca, R , Doroshow, J. H., and Petrelli, N. for the Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
86. Poon, M. A., O'Connel, J. H., Wieland, H. S. Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levin, R., Kardinal, C. G., and Maillard, J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
87. Jackman, A. L., Aherne, G., Kimbell, R., Brunton, L., Hardcastle, A., Wardleworth, J. W., Stephens, T. C., and Boyle, F. ZD9331, a non-polyglutamatable quinazoline thymidylate synthase (TS) inhibitor. Proc. Am. Assoc. Cancer Res., 35: 301, 1994.
88. Walton, M. I., Gibson, W., Aherne, L., Lawrence, N., Stephens, T., Smith, M., and Jackman, A. Pharmacokinetics of the potent non-polyglutamatable thymidylate synthase inhibitors CB30900 and ZD9331 in mice. Proc. Am. Assoc. Cancer Res., 35: 301, 1994.
89. Stephens, T. C., Smith, M. N., McClockey, M. L., and Boyle, F. T. ZD9331, a novel non-polyglutamated thymidylate synthase (TS) inhibitor: in vivo antitumor efficacy and toxicity to normal murine tissues. Proc. Am. Assoc. Cancer Res., 35: 305, 1994.
90. Pendergast, W., Dickerson, S. H., Johnson, J. V., Dev, I. K., Ferone, R., Duch, D. S., Hall, W. R., Humphreys, J., Kelly, I. M., and Wilson, D. C. Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino and 3-methylbenzo[f]quinazolin-1(2H)-ones. J. Med. Chem., 36: 2279-2291, 1993.
91. Duch, D. S., Banks, S., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., Humphreys, J., Knick, V., Pendergast, W., Singer, S., Smith, G., Waters, K., and Wilson, R. Biochemical and cellular pharmacology of 1849U89, a novel benzoqumazoline inhibitor of thymidylate synthase. Cancer Res., 53: 810-818, 1993.
92. Ferone, R., Hanlon, M. H., Waters, K. A., and Dev, I. K. Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89. Proc. Am. Assoc. Cancer Res., 34: 274, 1993.
93. Banks, S. D., Waters, K. A., Barrett, L. L., Dickerson, S., Pendergast, W., and Smith, G. K. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89. Cancer Chemother. Pharmacol. 36: 455-459, 1994.
94. Wilson, H. R., Heath, L S., Knick, V. C., Kszalka, G. W., and Ferone, R. In vivo antitumor activity of 1843U89, a new antifolate thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 33: 407, 1992
95. Boyd, M. R., and Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34: 91-109, 1995.
96. Jackson, R. C., Johnston, A. L., Shetty, B. V., Varney, M. D., and Webber, S. E. Molecular design of thymidylate synthase inhibitors. Proc. Am. Assoc. Cancer Res., 34: 566-567, 1993.
97. Varney, M. D., Marzone, G. H. P., Palmer, C. L., Reddy, M. R., Tatlock, J., Rommes, W. H., Wu, B. W., and Musick, L. Crystal-structure-based design and synthesis of benz[od]indole-containing inhibitors of thymidylate synthase. J. Med. Chem., 35: 663-676, 1992.
98. Reich, S. H., Fuhry, M. A. M., Nguyen, D., Pino, M. J., Welsh, K. M., Webber, S., Janson, C. A., Jordan, S. R., Matthews, D. A., Smith, W., and Bartlett, C. Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis. J. Med. Chem., 35: 847-858, 1992.
99. Webber, S., Shetty, B., Johnston, A., Welsh, K., Varney, M., Deal, J., Morse, C., and Soda, K. In vitro properties and antitumor activity of AG-331, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc Cancer Res., 33: 413, 1992.
100. Webber, S., Johnston, A., Shetty, B., Webber, S. E., Welsh, K., Hilliard, J., Kosa, M., Morse, C., and Soda, K. Preclinical studies on AG337, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 34: 273, 1993.
101. Boritzki, T. J., Bartlett, C. A., Huffaker, T., Morse, C. A., Webber, S., Welsh, K., and Jackson, R. C. Biochemical properties of new lipophilic thymidylate synthase inhibitors designed from the X-ray structure of the E. coli enzyme. Proc. Am. Assoc Cancer Res., 33: 33, 1992.
102. Clendeninn, N. J., Peterkin, J. J., Webber, S., Shetty, B. V., Koda, R. T , Leichman, L., Leichman, C. G., Jeffers, S , Muggia, F., and O'Dwyer, P. AG-331, a "non-classical" lipophilic thymidylate synthase inhibitor for the treatment of solid tumors Ann. Oncol., 5 (Suppl. 5): 133, 1994.
103. Calvete, J. A., Balmanno, K., Taylor, G. A., Rafi, I., Newell, D. R., Lind, M. J., Calvert, A. H., Webber, S., and Clendeninn, N. J. Preclinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337. Proc. Am. Assoc. Cancer Res., 35: 306, 1994.
104. Calvete, J. A., Balmanno, K., Rafi, I., Newell, D. R., Taylor, G. A., Boddy, A. V., Lind, M. J., Bailey, N. B., Calvert, A. H., Webber, S., and Clendeninn, N. J. Preclinical and clinical studies of the novel thymidylate synthase inhibitor AG337, given by oral administration. Proc. Am. Assoc. Cancer Res., 36: 380, 1995.
105. Rafi, I., Taylor, G. A., Balmanno, K., Calvete, J. A., Newell, D. R., Lind, M. J., and Calvert, A. H. A Phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by a 24 h intravenous continuous infusion. Proc. Am. Assoc. Cancer Res., 35: 306, 1994.
106. Johnson, P Agouron Initiates Phase II Efficacy Trials of Anti-Tumor Drus AG337. La Jolla, CA: Asouron Pharmaceuticals, Inc., 1994.
107. Boddy, A. V., Calvete, J. A., and Rafi, I. Non-linear pharmacokinetics in cancer patients of AG337, a rationally-designed thymidylate synthase (TS) inhibitor. Proc. Am. Assoc. Cancer Res., 36: 236, 1995.
108. Rafi, I., Taylor, G. A., Calvete, J. A., Balmanno, K., Boddy, A. V., Bailey, N B., Lind, M. J., Newell, D., Calvert, A. H., Johnston, A., and Clendeninn, N. J. A Phase I clinical study of the novel antifolate AG337 given by a 5-day continuous infusion. Proc. Am. Assoc. Cancer Res., 36. 240, 1995.
109. Koda, R. T., Leichman, L., Webber, S., Shetty, B. V., Leichman, C. G., Jeffers, S., and Muggia, F. M. Pharmacokinetics of AG-331 following single escalating i.v. doses in patients with refractory solid tumors. Proc. Am. Assoc. Cancer Res., 35. 432, 1994.
110. O'Connor, B. M., Webber, S., Jackson, R. C. Galivan, J., and Rhee, M. S. Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother. Pharmacol., 34: 225-229, 1994.
111. Jackman, A. L., Kelland, L. R., Brown, M., Gibson, W., Kimbell, R., Aherne, W., and Judson, I. R. ICI D 1694 resistant cell lines. Proc. Am. Assoc. Cancer Res., 33: 406, 1992.
112. Freemantle, S. J., Lunec, J., Jackman, A. L., Kelland, L. R., Aherne, G W., and Calvert, A. H. Molecular characterisation of three cell lines selected for resistance to folate-based thymidylate synthase inhibitors. Br. J. Cancer, 67 (Suppl. 20): 79, 1993.
113. Berger, S. H., Jenh, C. H., Johnson, L. F., and Berger, F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol., 28: 461-467, 1987.
114. Cowan, K. H., and Jolivet, J. A methotrexate-resistant human breast cancer cell line with multiple defects including diminished formation of methotrexate polyglulamates. J. Biol. Chem., 259: 10793-10800, 1984
115. Rosowsky, A., Wright, J. E., Cucchi, C. A., Lippke, J. A., Tantravahi, R., Ervin, T. J., and Frei, E. III. Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance. Cancer Res., 45. 6205-6212, 1985
116. Pizzorno, G., Mini, E., Coronnello, M., McGuire, J. J., Moroson, J. B. A., Cashmore, A. R., Dreyer, R. N., Lin, J. T., Mazzei, T., Periti, P., and Bertino, J. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high dose treatment with this drug. Cancer Res., 48: 2149-2155, 1988.
117. Shih, C., Grindey, G. B., Barnett, C. J., Pearce, H. L., Engelhardt, J. A., Todd, G. C., Rinzel, S. M , Worzalla, J F., Gossett, L. S., and Everson, T. P. Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc. Am. Assoc. Cancer Res., 33: 411, 1992.
118. Grindey, G. B., Shih, C , Barnett, C. J., Pearce, H. L., Engelhardt, J A., Todd, G C., Rinzel, S. M., Worzalla, J. F., Gossett, L. S., and Everson, T. P. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc. Am. Assoc. Cancer Res., 33: 411, 1992.
119. Rinaldi, D. A., Burris, H. A., Dorr, F. A., Nelson, J., Fields, S. M., Kuhn, J. G., Eckardt, J., Lu, P., Woodworth, J R., and Corso, S. W. A Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 13: 430, 1994.
120. Taylor, G. A., Rafi, I., Balmanno, K., Calvete, J. A., Newell, D. R., Webber, S., Jackson, R. C , Gumbrell, L., Chapman, F., and Oakey, A. Preclinical and early clinical studies with the lipophilic thymidylate synthase inhibitor, AG337. Br. J. Cancer., 67 (Suppl XX): 17, 1993.
121. Chu, E., Voeller, D., Koeller, D. M., Drake, J. C., Takimoto, C. H., Maley, G., Maley, F., and Allegra, C. J. Identification of an RNA binding site for human thymidylate synthase. Proc. Natl. Acad. Sci. USA, 90: 517-521, 1993.
122. Chu, E., Koeller, D. M., Casy, L. J., Drake, C J., Chabner, B. A., Elwood, P. C., Zinn, S., and Allegra, C. J. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA, 88: 8977-8981, 1991.
123. Chu, E., Zinn, S., Boarman, D., and Allegra, C. J. The interaction of interferon-γ and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res., 50: 5834-5840, 1990.
124. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, T. H. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res., 42. 450-456, 1982.
125. Keyomarsi, D., and Moran, R. G. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J. Biol. Chem., 263: 14402-14409, 1988.
126. Keyomarsi, K., Samet, J., Molnar, G., and Pardee, A. B. The thymidylate synthase inhibitor ICI D 1694 overcomes translational detainment of the enzyme. J. Biol. Chem., 268: 15132-15149, 1993.
127. Keyomarsi, K., Molnar, G., and Pardee, A. B. Loss of translational control of thymidylate synthase (TS) by antifolates results in the accumulation of the TS protein. Proc. Am. Assoc. Cancer Res., 34: 276, 1993.
128. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
129. Lowe, S. W , Bodis, S., McClathcey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo Science (Washington DC), 266: 807-810, 1994.
130. Oltvai, Z. N., and Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell, 79: 189-192, 1994.
131. Starzynska, T., Bromley, M., Ghosh, A., and Stern, P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66: 558-562, 1992.
132. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
133. Chu, E., Takechi, T., Jones, K. L., Voeller, D. M., Copur, S. M., Maley, G. F., Maley, F., Segal, S., and Allegra, C. J. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol. Cell. Pharmacol., 15: 179-185, 1995.
134. Chu, E., Copur, S., Jones, K. L., Khleif, S., Voeller, D., Maley, G. F., Maley, F., and Allegra, C. J. Thymidylate synthase regulates the translation of p53 mRNA. Proc. Am. Assoc. Cancer Res., 36: 563, 1995.
135. Arredondo, M. A., Yin, M. B., Lu, K., Schöber, C., Slocum, H., and Rustum, Y. M. Decreased c-myc protein accompanied by increased p53 and Rb is associated with thymidylate synthase inhibition and cell cycle retardation induced by D1694. Proc. Am. Assoc. Cancer Res., 35: 304, 1994.
136. Fisher, T. C., Milner, A. E., Gregory, C. D., Jackman, A. L., Aherne, G. W., Hartley, J. A., Dive, C., and Hickman, J. A. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res., 53: 3321-3326, 1993.
137. Lenz, H. J., Ju, J F., Danenberg, K. D., Leichman, L., Leichman, C., Haag, C., and Danenberg, P. V. TS levels and p53 function predict for response to 5-fluorouracil/leucovorin in patients with advanced colon cancer. Proc. Am. Soc. Clin. Oncol., 14: 202, 1995.
138. Kobayashi, H., Takemura, Y., Miyachi, H., Skelton, L., and Jackman, A. L. The effect of hammerhead ribozyme against thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 36: 342, 1995.
139. Weber, G., and Prajda, N. Targeted and non-targeted actions of anti-cancer drugs. Adv. Enzyme Regul., 34: 71-89, 1994.
140. Pressacco, J., and Erlichman, C. Combination studies with 3′-azido-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem. Pharmacol., 46: 1989-1997, 1993.
141. Pressacco, J., Hedley, D. W , and Erlichman, C. ICI D1694 and idoxuridine: a synergistic antitumor combination. Cancer Res. 54: 3772-3778, 1994.
142. Chang, Y. M., Zielinski, Z., Izzo, J., Porubcin, M., and Bertino, J. R. Pretreatment of colon carcinoma cells to D1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc. Am. Assoc. Cancer Res., 35: 330, 1994.
143. Izzo, J., Zielinski, Z., Chang, Y. M., and Bertino, J. R. Molecular mechanisms of the synergistic sequential administration of D1694 (Tomudex) followed by FUra in colon carcinoma cells. Proc. Am. Assoc. Cancer Res., 36: 381, 1995.
144. Van der Wilt, C. L., Pinedo, H. M., Kuiper, C. M., Smid, K., and Peters, G. J. Biochemical basis for the the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc. Am. Assoc. Cancer Res., 36: 379, 1995
145. National Cancer Institute PDQ. Phase I study of Tomudex in combination with 5-FU/CF/IFN-A for recurrent adult solid tumors including gastrointestinal, breast, lung, and ovarian carcinomas. Curr. Clin. Trials Oncol., 2: 749, 1995.